Does Aclaris Therapeutics, Inc. have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores Aclaris Therapeutics, Inc. (ACRS) 33.4 out of 100 — below the Shallow-moat bar, so no moat. The four filters behind that score (each 0–100): pricing power 59, returns on capital 0, balance-sheet safety 55, capital discipline 24.

How has ACRS's Moat Score changed over time?

The record logs 2 readings since Jul 17, 2026; the latest reads 33.4 out of 100 (no moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

Aclaris Therapeutics, Inc.

ACRS · Healthcare · $684.4M mkt cap · FY2025 filings · No moat ·

Doesn't clear the bar

No moat

The four filters

Pricing power59

Median gross margin 52.7% over 9y, variable.

Returns on capital0

Median ROIC -56.1%, above the 9% hurdle in 0% of years.

Balance-sheet safety55

Net cash position — no leverage risk.

Capital discipline24

Owner earnings trend unclear, share count growing (dilution).

Margin of safety

Above valueOn sale

No price data

Owner earnings (normalized): —
Est. intrinsic value / share: —
Recent price: $5.68
Discount to value: No price data

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

Fundamentals

There's no normalized fundamentals series for ACRS yet — it appears once ingest has processed its filings.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale33.4 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — ACRS has read No moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#322 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#320SEER Seer, Inc.33.8 out of 100, No moatNo moat
#321SINT Sintx Technologies, Inc.33.5 out of 100, No moatNo moat
#323MRMD MARIMED INC.33.3 out of 100, No moatNo moat
#324SGRY Surgery Partners, Inc.33.2 out of 100, No moatNo moat

Compare ACRS with its nearest peers →All Healthcare companies on the Index →

Common questions about ACRS

Does Aclaris Therapeutics, Inc. have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores Aclaris Therapeutics, Inc. (ACRS) 33.4 out of 100 — below the Shallow-moat bar, so no moat. The four filters behind that score (each 0–100): pricing power 59, returns on capital 0, balance-sheet safety 55, capital discipline 24.
How has ACRS's Moat Score changed over time?: The record logs 2 readings since Jul 17, 2026; the latest reads 33.4 out of 100 (no moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows ACRS’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/ACRS"
  width="340" height="150" style="border:0"
  title="ACRS Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell ACRS. See the disclaimer.